GlassScriptPhysician profile
Dale E Goins
NPI 1063402485
$487.42
in general payments reported to CMS, 2019-2025
14 companies · $33.51 in 2025
The $33.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.47 · 2020: $14.02 · 2021: $180 · 2022: $95.10 · 2023: $45.44 · 2024: $75.73 · 2025: $33.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.73 | 2022 | |
| Pfizer INC. | $66.55 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $49.96 | 2020-2021 | |
| Lilly USA, LLC | $39.77 | 2021-2025 | Mounjaro, Zepbound |
| Eisai INC. | $38.31 | 2023-2024 | |
| Harmony Biosciences LLC | $36.31 | 2024 | |
| Novo Nordisk INC | $32.31 | 2019 | |
| Biogen, INC. | $28.43 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $27.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.39 | 2019-2021 | |
| Lundbeck LLC | $18.49 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.15 | 2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $12.72 | 2023 | Quviviq |
| Astellas Pharma US INC | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Goins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.